Inflammatory chemokines are instrumental players in cancer-related inflammation contributing to numerous steps during tumor progression. In Kaposi's sarcoma, we have found that downregulation of the atypical chemokine receptor 2 (ACKR2) by the KRAS/BRAF/ERK pathway profoundly affects the tumor microenvironment, unleashing accumulation of tumor-associated macrophages that sustains tumor growth. This discovery extends our understanding on the role of inflammatory chemokines in tumor biology and provides rationale for their therapeutic targeting.
Atypical chemokine receptor 2: a brake against Kaposi's sarcoma aggressiveness / R. Bonecchi, B. Savino, N. Caronni, G. Celesti, A. Mantovani, M. Locati. - In: ONCOIMMUNOLOGY. - ISSN 2162-4011. - 3:12(2015), pp. e955337.1-e955337.3. [10.4161/21624011.2014.955337]
Atypical chemokine receptor 2: a brake against Kaposi's sarcoma aggressiveness
R. Bonecchi
Primo
;B. SavinoSecondo
;N. Caronni;G. Celesti;A. MantovaniPenultimo
;M. LocatiUltimo
2015
Abstract
Inflammatory chemokines are instrumental players in cancer-related inflammation contributing to numerous steps during tumor progression. In Kaposi's sarcoma, we have found that downregulation of the atypical chemokine receptor 2 (ACKR2) by the KRAS/BRAF/ERK pathway profoundly affects the tumor microenvironment, unleashing accumulation of tumor-associated macrophages that sustains tumor growth. This discovery extends our understanding on the role of inflammatory chemokines in tumor biology and provides rationale for their therapeutic targeting.
| File | Dimensione | Formato | |
|---|---|---|---|
|
oncoimmunology.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
181.04 kB
Formato
Adobe PDF
|
181.04 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
